Disc Medicine COO exercises options, sells 9,700 shares

Disc Medicine, Inc. Chief Operating Officer Jonathan Yu Yen-Wen executed an options-related trade involving company stock.

Rhea-AI Filing Summary

Disc Medicine, Inc. Chief Operating Officer Jonathan Yu Yen-Wen executed an options-related trade involving company stock. He exercised stock options to acquire 9,700 shares of common stock at $13.50 per share, then sold 9,700 shares in an open-market transaction at a weighted average price of $72.6593 per share.

The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026. Following these trades, he directly holds 54,324 shares of common stock and 24,147 stock options that are scheduled to vest monthly through December 29, 2026 and expire on December 28, 2032.

Insider Trade Summary 10b5-1

Exercise and Sale: 9,700 shares ($574K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Yu Jonathan Yen-Wen

Role Chief Operating Officer

Sold 9,700 shs ($705K)

Approx. gross sale proceeds $705K

Approx. exercise cost $131K

Approx. pre-tax spread $574K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	9,700	$0.00	$0.00
Exercise	Common Stock	9,700	$13.50	$131K
Sale	Common Stock	9,700	$72.6593	$705K

Holdings After Transaction: Stock Option (Right to Buy) — 24,147 contracts (Direct); Common Stock — 54,324 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.50 to $72.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
3. F3. The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Shares sold: 9,700 shares Sale price: $72.6593 per share Options exercise price: $13.50 per share +5 more

8 metrics

Shares sold 9,700 shares Open-market sale of common stock on June 22, 2026

Sale price $72.6593 per share Weighted average sale price for 9,700 shares

Options exercise price $13.50 per share Exercise price of stock options converted into 9,700 shares

Common shares after trade 54,324 shares Direct common stock holdings after reported transactions

Options remaining after trade 24,147 options Stock options held after exercise, expiring December 28, 2032

Rule 10b5-1 plan adoption date March 17, 2026 Date COO adopted trading plan used for these transactions

Sale price range $72.50–$72.68 per share Range of individual transaction prices within reported sale

Option expiration December 28, 2032 Expiration date of the stock option grant exercised in part

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), Exercise or conversion of derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

vest in 48 equal monthly installments financial

"The shares underlying this option vest in 48 equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Disc Medicine (IRON) COO Jonathan Yu Yen-Wen do in this Form 4 filing?

He exercised stock options to acquire 9,700 Disc Medicine shares at $13.50 each, then sold 9,700 shares at a weighted average of $72.6593. The filing shows an options-related exercise-and-sell transaction executed under a pre-arranged Rule 10b5-1 trading plan.

How many Disc Medicine (IRON) shares did the COO sell and at what price?

He sold 9,700 shares of Disc Medicine common stock in an open-market transaction at a weighted average price of $72.6593 per share. Footnotes state these were multiple trades within a $72.50 to $72.68 range, reported as a single weighted average price.

What options did the Disc Medicine (IRON) COO exercise in this Form 4?

He exercised stock options covering 9,700 shares of Disc Medicine common stock at a conversion or exercise price of $13.50 per share. These options are part of a larger grant that vests in 48 equal monthly installments starting December 29, 2022, subject to continued service.

How many Disc Medicine (IRON) shares and options does the COO hold after the transactions?

After the reported transactions, he directly holds 54,324 shares of Disc Medicine common stock and 24,147 stock options. The remaining options, with a $13.50 exercise price, are scheduled to vest monthly and expire on December 28, 2032, according to the filing details.

Were the Disc Medicine (IRON) insider transactions under a Rule 10b5-1 plan?

Yes. A footnote explains that the transactions were executed under a Rule 10b5-1 trading plan adopted on March 17, 2026. Such plans allow insiders to pre-schedule trades, which can make the timing of sales less indicative of their current market views.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 08:34 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Jonathan Yen-Wen

(Last) (First) (Middle)

C/O DISC MEDICINE, INC.

321 ARSENAL STREET, SUITE 101

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		M(1)		9,700	A	$13.5	64,024	D
Common Stock	06/22/2026		S(1)		9,700	D	$72.6593(2)	54,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.5	06/22/2026		M(1)			9,700	(3)	12/28/2032	Common Stock	9,700	$0	24,147	D

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.50 to $72.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

3. The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

	By: /s/ Rahul Khara, as Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)